Parallel decline of CD8+CD38+ lymphocytes and viremia in treated hepatitis B patients

World Journal of Gastroenterology

Volumn 17, Issue 17, 2011, Pages 2191-2198

  Cao, Wei ^a   Qiu, Zhi Feng ^a   Li, Tai Sheng ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Chronic hepatitis B; Hepatitis B virus; T cell subsets

Indexed keywords

ADEFOVIR DIPIVOXIL; BIOLOGICAL MARKER; CD28 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PERIPHERAL LYMPHOCYTE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; VIREMIA; VIRUS CARRIER; VIRUS LOAD;

EID: 79955862637     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i17.2191     Document Type: Article

References (30)

1. World Health Organization, Department of Communicable diseases surveillance and response. Hepatitis B. WHO Fact Sheets. Accessed: July 28, 2010. Available from: URL: http://www.who.int.
2. Maini MK, Boni C, Ogg GS, King AS, Reignat S, Lee CK, Larrubia JR, Webster GJ, McMichael AJ, Ferrari C, Williams R, Vergani D, Bertoletti A. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 1999; 117: 1386-1396
3. Baumert TF, Thimme R, von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13: 82-90
4. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol 2006; 87: 1439-1449
5. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov NV, Ferrari C, Bertoletti A. The role of virus-specifc CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191: 1269-1280
6. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60
7. Bertoni R, Sidney J, Fowler P, Chesnut RW, Chisari FV, Sette A. Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest 1997; 100: 503-513
8. You J, Zhuang L, Zhang YF, Chen HY, Sriplung H, Geater A, Chongsuvivatwong V, Piratvisuth T, McNeil E, Yu L, Tang BZ, Huang JH. Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load. World J Gastroenterol 2009; 15: 3382-3393
9. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-975
10. You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Li YL, Lei H, Liu J, Chen HY, Tang BZ, Huang JH. Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients. BMC Infect Dis 2008; 8: 123
11. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, Cavalli A, Urbani S, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33: 963-971
12. Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS 2000; 14: 1079-1089
13. Bofll M, Borthwick NJ. CD38 in health and disease. Chem Immunol 2000; 75: 218-234
14. Tilling R, Kinloch S, Goh LE, Cooper D, Perrin L, Lampe F, Zaunders J, Hoen B, Tsoukas C, Andersson J, Janossy G. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS 2002; 16: 589-596
15. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiff-man ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816
16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wul-fsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807
17. Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, Ji BN, Chang CN, Barker KF. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006; 44: 108-116
18. Lok ASF, McMahon BJ. AASLD Practice guidelines chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36
19. Lau GK, Cooksley H, Ribeiro RM, Powers KA, Shudo E, Bowden S, Hui CK, Anderson J, Sorbel J, Mondou E, Rousseau F, Lewin S, Perelson AS, Locornini S, Naoumov NV. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther 2007; 12: 705-718
20. Pham BN, Mosnier JF, Walker F, Njapoum C, Bougy F, Degott C, Erlinger S, Cohen JH, Degos F. Flow cytometry CD4+/CD8+ ratio of liver-derived lymphocytes correlates with viral replication in chronic hepatitis B. Clin Exp Immunol 1994; 97: 403-410
21. Lynne JE, Schmid I, Matud JL, Hirji K, Buessow S, Shlian DM, Giorgi JV. Major expansions of select CD8+ subsets in acute Epstein-Barr virus infection: comparison with chronic human immunodeficiency virus disease. J Infect Dis 1998; 177: 1083-1087
22. Belles-Isles M, Houde I, Lachance JG, Noël R, Kingma I, Roy R. Monitoring of cytomegalovirus infections by the CD8+CD38+ T-cell subset in kidney transplant recipients. Transplantation 1998; 65: 279-282
23. Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV. CD8+ T-lymphocyte activation in HIV-1 disease refects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 332-340
24. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, Hamann D, Prins M, Miedema F. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17: 1881-1888
25. Simonelli C, Nasti G, Vaccher E, Tirelli U, Zanussi S, De Paoli P, Comar M, Giacca M. Hydroxyurea treatment in HIV-infected patients. J Acquir Immune Defc Syndr Hum Ret-rovirol 1996; 13: 462-464
26. Margolis DM, Kewn S, Coull JJ, Ylisastigui L, Turner D, Wise H, Hossain MM, Lanier ER, Shaw LM, Back D. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellu-lar deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defc Syndr 2002; 31: 45-49
27. Read SW, DeGrezia M, Ciccone EJ, DerSimonian R, Higgins J, Adelsberger JW, Starling JM, Rehm C, Sereti I. The effect of lefunomide on cycling and activation of T-cells in HIV-1-infected participants. PLoS One 2010; 5: e11937
28. Minguela A, Miras M, Bermejo J, Sánchez-Bueno F, López-Alvarez MR, Moya-Quiles MR, Muro M, Ontañón J, Garía-Alonso AM, Parrilla P, Alvarez-López MR. HBV and HCV infections and acute rejection differentially modulate CD95 and CD28 expression on peripheral blood lymphocytes after liver transplantation. Hum Immunol 2006; 67: 884-893
29. Choremi-Papadopoulou H, Panagiotou N, Samouilidou E, Kontopidou F, Viglis V, Antoniadou A, Kosmidis J, Kordossis T. CD28 costimulation and CD28 expression in T lymphocyte subsets in HIV-1 infection with and without progression to AIDS. Clin Exp Immunol 2000; 119: 499-506
30. Ostrowski SR, Gerstoft J, Pedersen BK, Ullum H. A low level of CD4+CD28+ T cells is an independent predictor of high mortality in human immunodefciency virus type 1-in-fected patients. J Infect Dis 2003; 187: 1726-1734